share_log

Nova Mentis Is Looking To Treat Autism With Psilocybin

Nova Mentis Is Looking To Treat Autism With Psilocybin

Nova Mentis正在寻求用裸盖菇素治疗自闭症
Benzinga Real-time News ·  2022/04/07 14:46

Nova Mentis Life Science Corp. (OTCQB:NMLSF) and the private college Toronto Institute of Pharmaceutical Technology have signed a contract for the production of psilocybin capsules. The company will supply the microdose capsules for a Phase 2A fragile X syndrome (FXS) clinical study.

Nova Mentis生命科学公司OTCQB:NMLSF)和私立学院多伦多制药技术学院签署了一份生产裸盖菇素胶囊的合同。该公司将为脆性X综合征(FXS)2A期临床研究提供微剂量胶囊。

FXS, also known as Martin-Bell syndrome, is one of the largest genetic causes of autism spectrum disorders.

FXS,也被称为马丁-贝尔综合征,是导致自闭症谱系障碍的最大遗传原因之一。

"The recently completed preclinical study of repeat low doses of our psilocybin drug—every other day for 2 weeks—showed clinical responses that greatly exceeded our expectations. We significantly modulated behavioral and cognitive defects, such as recognition memory, in FXS," commented Marvin S. Hausman, MD, chairman of Nova's scientific advisory board.

"最近完成的重复低剂量裸盖菇素药物的临床前研究--每隔一天服用一次,持续两周--显示出的临床反应大大超出了我们的预期。。我们显著地调节了FXS中的行为和认知缺陷,如识别记忆马文·S·豪斯曼,医学博士,诺瓦科学顾问委员会主席。

According to the company, a clinical trial application to Health Canada is expected for submission in the following weeks.

据该公司称,加拿大卫生部的临床试验申请预计将在接下来的几周内提交.

Almost two months ago, the Nova Mentis team announced that they encountered positive results in a preclinical study in Rome, Italy. In March, they announced that enrollment for the study in North America had commenced.

近两个月前,Nova Mentis团队宣布,他们在一项罗马的临床前研究、意大利。三月份,他们宣布该研究在北美的招生工作已经开始.

The company is showing great interest in developing a viable way of reducing the negative effects of FXS. Only time will tell if future clinical trials meet the same (or greater) kind of success that preclinical studies found.

该公司对开发一种可行的方法来减少FXS的负面影响表现出极大的兴趣。只有时间才能告诉我们,未来的临床试验是否会取得与临床前研究相同(或更大)的成功。

Photo courtesy from Wikimedia Commons

图片由维基媒体共享提供

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发